April 24 - A U.S. judge on Thursday rejected a bid by compounding pharmacies to keep making copies of Novo Nordisk's popular diabetes and weight-loss drugs Ozempic and Wegovy while a legal challenge ...

A quick spray of medication might seem like an easy way to get thicker hair, but some people say one sold online has left ...

Abbott’s ABT diversified business portfolio is well-positioned to drive continued momentum in 2025 amid foreign exchange ...

Bullish option flow detected in Hims and Hers Health with 16,443 calls trading, 1.2x expected, and implied vol increasing almost 7 points to ...

Reported side effects include "erectile dysfunction, anxiety, suicidal ideation, brain fog, depression, fatigue, insomnia, ...

Health-care companies ticked up as traders awaited earnings. Shares of Big Pharma company Merck ticked down ahead of its earnings. Summit Therapeutics shares rallied after its lung cancer drug ...

These hair aid products, which are in spray and serum formats, are not approved by the FDA but they are available via a ...

Eli Lilly is suing four telehealth companies that prescribe compounded versions of the pharmaceutical company's weight loss ...

According to the FDA, they have not received official approval, and no comprehensive safety data has been submitted for them.

Philip Morris International gave its earnings outlook a bump after sustained momentum for its popular Zyn pouch brand powered its profit and revenue higher in the first quarter. Warner shifted to a ...

Hims & Hers stock has dropped over 60% from its peak due to concerns about its GLP-1 business. Read why I think HIMS stock is ...